Guajaverin

Guajaverin

SCHEMBL3635416

O=c1c(O[C@@H]2OC[C@H](O)[C@H](O)[C@H]2O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.71
AKR1B1 P15121 6/20 0.71
P4HB P07237 5/20 0.71
EPHX2 P34913 5/20 0.71
MAOA P21397 4/20 0.71
XDH P47989 4/20 0.71
L3MBTL1 Q9Y468 3/20 0.71
SLCO2B1 O94956 3/20 0.71
PIM2 Q9P1W9 2/20 0.71
ALDH1A1 P00352 2/20 0.71
CA12 O43570 2/20 0.71
CA2 P00918 2/20 0.71
CA4 P22748 2/20 0.71
CA7 P43166 2/20 0.71
GAA P10253 7/20 0.69
POLB P06746 6/20 0.69
MAPT P10636 6/20 0.69
ALPI P09923 2/20 0.69
LMNA P02545 2/20 0.69
ADRA2C P18825 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Reynoutrin SCHEMBL31130799 1.00 KDM4E (0.71) KDM4EAKR1B1P4HBEPHX2MAOA
Reynoutrin SCHEMBL14350762 1.00 KDM4E (0.71) KDM4EAKR1B1P4HBEPHX2MAOA
Reynoutrin SCHEMBL3641504 1.00 KDM4E (0.71) KDM4EAKR1B1P4HBEPHX2MAOA
Reynoutrin SCHEMBL4226891 1.00 KDM4E (0.71) KDM4EAKR1B1P4HBEPHX2MAOA
Reynoutrin SCHEMBL38138 1.00 KDM4E (0.71) KDM4EAKR1B1P4HBEPHX2MAOA
Reynoutrin SCHEMBL5590747 1.00 KDM4E (0.71) KDM4EAKR1B1P4HBEPHX2MAOA
Reynoutrin SCHEMBL20298285 1.00 KDM4E (0.71) KDM4EAKR1B1P4HBEPHX2MAOA
Reynoutrin SCHEMBL6759025 1.00 KDM4E (0.71) KDM4EAKR1B1P4HBEPHX2MAOA
Reynoutrin SCHEMBL6119167 1.00 KDM4E (0.71) KDM4EAKR1B1P4HBEPHX2MAOA
Reynoutrin SCHEMBL28550462 1.00 KDM4E (0.71) KDM4EAKR1B1P4HBEPHX2MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115449798-A Acer truncatum leaf steel corrosion inhibitor and preparation method thereof 北京科技大学 2022-12-09 CN claimed
CN-113080268-A Purple tea and purple tea extract with antioxidant and/or hypoglycemic activities, and preparation method and application thereof 中国科学院昆明植物研究所 2021-07-09 CN claimed
EP-3413727-A1 COMPOSITION CONTAINING GUAIJAVERIN FOR REDUCING AND/OR SUPPRESSING AN INTESTINAL GLUCOSE RESORPTION, NUTRITIONAL SUPPLEMENT, USE OF THE COMPOSITION AND PROCESS FOR PRODUCING THE NUTRITIONAL SUPPLEMENT PM-International AG (LU) 2018-12-19 EP claimed
WO-2017137405-A1 COMPOSITION CONTAINING GUAIJAVERIN FOR REDUCING AND/OR SUPPRESSING AN INTESTINAL GLUCOSE RESORPTION, NUTRITIONAL SUPPLEMENT, USE OF THE COMPOSITION AND PROCESS FOR PRODUCING THE NUTRITIONAL SUPPLEMENT PM-INTERNATIONAL AG (LU) 2017-08-17 WO claimed
EP-3052202-A1 SKIN TANNING EXTRACT DSM IP Assets B.V. (NL) 2016-08-10 EP claimed
WO-2015049366-A1 SKIN TANNING EXTRACT DSM IP ASSETS B.V. (NL) 2015-04-09 WO claimed
CN-118225913-A Method for detecting multiple components in aizoon stonecrop based on UPLC-QTOF-MS 江阴天江药业有限公司 2024-06-21 CN disclosed
CN-115449798-A Acer truncatum leaf steel corrosion inhibitor and preparation method thereof 北京科技大学 2022-12-09 CN disclosed
CN-113080268-A Purple tea and purple tea extract with antioxidant and/or hypoglycemic activities, and preparation method and application thereof 中国科学院昆明植物研究所 2021-07-09 CN disclosed
EP-3780974-A1 GUAVA EXTRACT PM-International AG (LU) 2021-02-24 EP disclosed
WO-2019201425-A1 GUAVA EXTRACT PM-INTERNATIONAL AG (LU) 2019-10-24 WO disclosed
US-10293013-B2 Water soluble Psidium guajava leaf extract having standardized phytochemicals PHYTOTECH EXTRACTS PVT LTD (IN) 2019-05-21 US disclosed
US-20170080039-A1 WATER SOLUBLE PSIDIUM GUAJAVA LEAF EXTRACT HAVING STANDARDIZED PHYTOCHEMICALS PHYTOTECH EXTRACTS PVT LTD (IN) 2017-03-23 US disclosed
EP-3052202-A1 SKIN TANNING EXTRACT DSM IP Assets B.V. (NL) 2016-08-10 EP disclosed
WO-2015136454-A1 WATER SOLUBLE PSIDIUM GUAJAVA LEAF EXTRACT HAVING STANDARDIZED PHYTOCHEMICALS PHYTOTECH EXTRACTS PVT LTD (IN) 2015-09-17 WO disclosed
WO-2015049366-A1 SKIN TANNING EXTRACT DSM IP ASSETS B.V. (NL) 2015-04-09 WO disclosed
WO-2015016428-A1 ANTIVIRAL COMPOSITION FOR FISH CONTAINING QUERCETIN AS ACTIVE INGREDIENT 한국기초과학지원연구원 (KR) 2015-02-05 WO disclosed
EP-2144621-A2 GUAVA EXTRACT OMNICA GMBH (DE) 2010-01-20 EP disclosed
WO-2009027849-A2 GUAVA EXTRACT OMNICA GMBH (US) 2009-03-05 WO disclosed
US-20080293644-A1 GUAVA EXTRACT OMNICA GMBH (DE) 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293644-A1 GUAVA EXTRACT DPP4, DPP8, DPP3 KDM4E 529/4885AKR1B1 3307/4885P4HB 1667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.